VX-993 clinical trials
Also written VX-993.
How each study uses VX-993 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VX-993 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VX-993
- 9
Studies by the year they started
9 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test VX-993.
- Mar 2027Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyPhase 2 · Vertex Pharmaceuticals Incorporated
Studies
Open first, then newest update. How each study uses VX-993 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyRecruitingPhase 2Vertex Pharmaceuticals IncorporatedNCT06619860Written as VX-993
- A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a BunionectomyCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT06619847Written as VX-993
- A Microneurography Study of NaV1.8 Inhibition in Healthy AdultsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06420765Written as VX-993
- A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy AdultsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06394167Written as VX-993
- Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy AdultsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06523595Written as VX-993
- A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993CompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06508762Written as VX-993
- A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy AdultsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06392659Written as VX-993
- A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993CompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06226454Written as VX-993
- A Phase 1 Dose Escalation Study of VX-993 in Healthy ParticipantsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT05653323Written as VX-993